Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. The Cooperative Study Group for Esophageal Cancer in Japan

Cancer Invest. 1995;13(4):363-9. doi: 10.3109/07357909509031916.


The aim of this report is to evaluate retrospectively the data from a prospective randomized study of 158 esophageal cancer patients who actually completed therapy with protein-bound polysaccharide P (PSK) and the 5-year survivals with and without raised alpha 1-antichymotrypsin and sialic acid levels to determine the value of these parameters in predicting effectiveness of immunotherapy. There was a significant difference in survival between the patients with and without PSK therapy. The survival of the radiochemotherapy plus PSK group treated for > 3 months was significantly better than that of the radiochemotherapy group. Among the patients with abnormal levels of alpha 1-antichymotrypsin and sialic acid, those who received PSK may have a significantly better survival than those without PSK. These results indicate that the preoperative serum levels of alpha 1-antichymotrypsin and sialic acid may possibly predict the effectiveness of immunotherapy using PSK.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibiotics, Antineoplastic / therapeutic use*
  • Biomarkers, Tumor / blood*
  • Combined Modality Therapy
  • Esophageal Neoplasms / blood*
  • Esophageal Neoplasms / immunology
  • Esophageal Neoplasms / therapy*
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Immunotherapy*
  • Male
  • Middle Aged
  • N-Acetylneuraminic Acid
  • Predictive Value of Tests
  • Proteoglycans / therapeutic use*
  • Retrospective Studies
  • Sialic Acids / blood
  • alpha 1-Antichymotrypsin / blood


  • Antibiotics, Antineoplastic
  • Biomarkers, Tumor
  • Immunologic Factors
  • Proteoglycans
  • Sialic Acids
  • alpha 1-Antichymotrypsin
  • polysaccharide-K
  • N-Acetylneuraminic Acid